This study thus suggests that hsa-miR-143-3p might play critical roles in regulating both tau function and APP processing by directly targeting DAPK1 and thus offers a potential novel therapeutic strategy for AD treatment. The gene discussed is MAPT; the disease is Alzheimer disease.